- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What Are the Effects of Not Expanding Medicaid?
Why Medicaid expansion represents an opportunity to improve the welfare of the poorest Americans, who are still recovering from the Great Recession.
An essential provision of the Affordable Care Act (ACA) is expanding Medicaid coverage to low-income Americans (those with incomes less than 138% of the federal poverty level). However, a Supreme Court decision in 2012 made Medicaid expansion optional for states and currently 38 states plus the District of Columbia have agreed to do so. From 2014 to 2016, the federal government will cover 100% of expansion cost. Afterward, federal support will decline each year, reaching and remaining at 90% by 2020.
Medicaid expansion has of course become a highly politicized issue, partly because it represents one of the few opportunities Republicans have to express disagreement with the ACA through policy, instead of voting on bills with no chance of leaving Congress.
Read more at the Brookings Institute: http://brook.gs/1B12Euw
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
